BEN domain containing 7 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored BEND7P1 profile across patient tissues and cancer cell-line models. BEND7P1 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, BEND7P1 is differentially expressed in 4, with the highest sampling consensus in ESCA. Additionally, BEND7P1 RNA expression shows 14,091 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, ESCA, and GBM as cancer lineages where BEND7P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BEND7P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BEND7P1 survival associations across molecular data types. BEND7P1 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BEND7P1 RNA expression–survival associations across cancer types. High BEND7P1 expression shows unfavorable associations in LIHC, KIRC, TGCT, THCA and BLCA, but favorable associations in BRCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for BEND7P1 RNA expression.
This table summarizes BEND7P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in ESCA for RNA.
This table ranks reproducible tumor–normal expression differences for BEND7P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BEND7P1 shows lower tumor expression in THCA and higher tumor expression in ESCA, CHOL and KIRC. The ESCA box plot shows higher BEND7P1 RNA expression in tumor versus normal tissue (log2 FC = +0.210, t-test p = .030).
This table shows molecular features associated with BEND7P1 in patient tissues and cancer cell lines. In patient samples, BEND7P1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
